Connection

Amy Sion to Recombinant Fusion Proteins

Back to Details
This is a "connection" page, showing publications Amy Sion has written about Recombinant Fusion Proteins.
Amy Sion
Connection Strength
0.035
Recombinant Fusion Proteins
  1. ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial. Lancet Oncol. 2018 05; 19(5):694-704.
    View in: PubMed
    Score: 0.035
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.